BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20220101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230417
DTEND;VALUE=DATE:20230420
DTSTAMP:20260516T055813
CREATED:20221215T130847Z
LAST-MODIFIED:20221215T130847Z
UID:36096-1681689600-1681948799@www.pharmajournalist.com
SUMMARY:2nd LNP Formulation & Process Development Summit
DESCRIPTION:Turbocharging Your Next Gen LNP End-To-End Development to Deliver Curative Promises to Patients \nFollowing exciting industry updates from Verve Therapeutics’ GalNAc-LNP for PCSK9 for HFpEF treatment\, to Recode’s 5th element\, the 2nd LNP Formulation & Process Development Summit is your must-attend meeting as this nanoparticle continues to dominate the biopharmaceutical industry in 2023. \nNew for 2023\, we have curated 3 streams of content for 2nd iteration of the summit: \n\nIn depth discussions divulging IP and regulatory compliance for LNP drug products\nMaximized LNP flexibility and versatility for payloads beyond mRNA vaccines with other RNA\, DNA\, gene therapy and gene editing possibilities\nLipid Chemistry & Discovery Track: Novel lipid discovery and particle engineering to customize LNP composition for next generation delivery vehicle\nFormulation & Process Development Track: Optimize your LNP development techniques for enhanced manufacturability and product quality\, and overcome stability issues of LNP-nucleic acid drug products\nLNP CMC & Manufacturing Track: Elevating your process control\, CQAs framework for CMC\, GMP compliance for seamless scale-up\n\nThis summit will offer the most comprehensive content and exclusive data\, equipping you with end-to-end LNP development journey to exploit this lucrative non-viral delivery vehicle for various payloads to your destined cells and organs. \nIn collaboration with Intellia Therapeutics\, Pfizer\, Sanofi\, ReCode Therapeutics\, Akagera Medicines\, the 2nd LNP Formulation & Process Development Summit is committed to serving you with their lessons learned to supercharge your pipeline and deliver curative promises to patients. \nJoin us to stay at the forefront of science\, network with 350+ LNP Biology\, Chemistry\, Formulation & Process Development\, Tech Ops & Manufacturing experts to gain competitive advantage to exploit LNP potentials! \nTo know more visit: https://ter.li/ol6e27
URL:https://www.pharmajournalist.com/event/2nd-lnp-formulation-process-development-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230418
DTEND;VALUE=DATE:20230421
DTSTAMP:20260516T055813
CREATED:20230119T091650Z
LAST-MODIFIED:20230119T091650Z
UID:36291-1681776000-1682035199@www.pharmajournalist.com
SUMMARY:3rd Fc Receptor Pathway Targeted Therapies 2023
DESCRIPTION:The field of FcRn receptor targeting is gaining ground-breaking speed as Argenx\, Janssen\, UCB and Immunovant compete to tackle myasthenia gravis and biopharma invest in transformative immunological therapy for autoimmune diseases as the next big drug opportunity. \nThe 3rd Fc Receptor Pathway Targeted Therapies Summit will once again feature unmissable conversations to advance targeting FcR and the subsequent generation of Fc manipulation since real-world proof and clinical value are now at the industry’s fingertips. \nJoin 100+ of your colleagues at the 3rd Fc Receptor Pathway Targeted Therapies Summit – from the fields of immunology\, antibody engineering\, pharmacology\, toxicology\, and immuno-oncology for three days of content that is unmatched in its scope\, all focused on the optimization of FcRn\, FcγR\, and novel Fc. \nPut your stake in the ground to revolutionise autoimmune illness and position yourself in front of the next wave of blockbuster drug development. \nTo know more visit: https://ter.li/y9vxt6
URL:https://www.pharmajournalist.com/event/3rd-fc-receptor-pathway-targeted-therapies-2023/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230418
DTEND;VALUE=DATE:20230421
DTSTAMP:20260516T055813
CREATED:20230127T095023Z
LAST-MODIFIED:20230127T095023Z
UID:36387-1681776000-1682035199@www.pharmajournalist.com
SUMMARY:mRNA Process Development & Manufacturing Europe
DESCRIPTION:mRNA therapeutics have catapulted into the limelight amidst the COVID-19 pandemic with multiple EMA approvals to help combat the virus. \nBringing together KOLs sharing case studies with actionable insights\, the inaugural mRNA Process Development & Manufacturing Summit Europe has been established as the first forum in Europe to support your in-house process development and manufacturing strategies. \nThe 3-day agenda has been carefully co-authored along with the leaders within the industry from the likes of BioNTech\, AstraZeneca and Genentech. A snapshot of key topics include: \n\nAssessing how dsRNA formation can be limited to reduce the purification requirements of the manufacturing process with BioNTech SE\nUncovering how to maximise biocomparability when scaling up the batch manufacturing process\, including identifying the critical process steps that introduce batch-to-batch variability with Genentech & Roche\nA snapshot of robust\, high-throughput online novel assays for identifying impurities with CureVac & AstraZeneca\nUnderstanding critical quality attributes and the differences in process development considerations for mRNA therapeutics and vaccines to achieve appropriate drug substance quality with the University of Sheffield & University Hospital Zurich\nHearing how the global market could function with a standard process platform to benefit all patients with Medicines Patent Pool\n\nThis is an opportunity to join 80+ mRNA enthusiasts from mRNA manufacturing\, analytics\, process development\, CMC\, quality control\, and drug substance to get key insights on scaling up mRNA drug substances in Europe whilst navigating mRNA process development and manufacturing regulatory guidelines to create commercially successful mRNA vaccines and therapeutics. \nTo know more visit: https://ter.li/f3ec38
URL:https://www.pharmajournalist.com/event/mrna-process-development-manufacturing-europe/
LOCATION:Sheraton Offenbach Hotel\, Am Buesing Palais\, Berliner Str. 111\,\, Offenbach am Main\, 63065\, Germany
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR